Although the NB cells harboring different types of ALK mutations are not identically sensitive to the inhibitors available at present [158], the results inspire the development of novel antitumor compounds and more effective therapeutic strategy targeting ALK for the patients with mutated ALK. Indeed, Phase I/II clinical trials of the ALK inhibitor crizotinib for NB are ongoing in the USA. This evidence concerns the gene ALK and neuroblastoma.